Skip to main content
SpringerLink
Log in

Combination Therapy in Hypertension Treatment

  • Chapter
  • First Online:
Managing the Kidney when the Heart is Failing

Abstract

Hypertension guidelines have recommended to lower blood pressures to at least 140/90 mmHg to prevent cardiovascular diseases. However, initiating monotherapy to hypertensive patients, especially with difficult-to-treat hypertension, fails to lower blood pressure to the desired goal. The formulation of single-pill combinations or fixed-dose combinations has made therapeutic management of hypertension less complicated. They have the same efficacy as the single agent, allow patient adherence, and at the same time lower the side effects if maximum doses of the single agent are given. However, cost still remains an issue since most of these drugs are not generic. In the future, there will be triple combination pills and even the polypill which show promise in the management of hypertension.

Originally published in Bakris, The Kidney in Heart Failure, ISBN: 978-1-4614-3693-5

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA. 2003;290(2):199–206.

    Article  PubMed  Google Scholar 

  2. Franklin SS, Jacobs MJ, Wong ND, L’Italien GJ, Lapuerta P. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension. 2001;37(3):869–74.

    Article  PubMed  CAS  Google Scholar 

  3. Fields LE, Burt VL, Cutler JA, Hughes J, Roccella EJ, Sorlie P. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension. 2004;44(4):398–404.

    Article  PubMed  CAS  Google Scholar 

  4. Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE, Roccella EJ. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988–1994 and 1999–2004. Hypertension. 2008;52(5):818–27.

    Article  PubMed  CAS  Google Scholar 

  5. Macmahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335(8692):765–74.

    Article  PubMed  CAS  Google Scholar 

  6. Asia Pacific Cohort Studies Collaboration. Joint effects of systolic blood pressure and serum cholesterol on cardiovascular disease in the Asia Pacific region. Circulation. 2005;112(22):3384–90.

    Google Scholar 

  7. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560–72.

    Article  PubMed  CAS  Google Scholar 

  8. Waeber B, Brunner HR. Low-dose combinations versus monotherapies in the treatment of hypertension. J Hypertens Suppl. 1997;15(2):S17–20.

    PubMed  CAS  Google Scholar 

  9. Brunner HR, Menard J, Waeber B, et al. Treating the individual hypertensive patient: considerations on dose, sequential monotherapy and drug combinations. J Hypertens. 1990;8(1):3–11.

    Article  PubMed  CAS  Google Scholar 

  10. Khanna A, Lefkowitz L, White WB. Evaluation of recent fixed-dose combination therapies in the management of hypertension. Curr Opin Nephrol Hypertens. 2008;17(5):477–83.

    Article  PubMed  CAS  Google Scholar 

  11. White WB. Improving blood pressure control and clinical outcomes through initial use of combination therapy in stage 2 hypertension. Blood Press Monit. 2008;13(2):123–9.

    Article  PubMed  Google Scholar 

  12. Rosenthal T, Gavras I. Fixed-drug combinations as first-line treatment for hypertension. Prog Cardiovasc Dis. 2006;48(6):416–25.

    Article  PubMed  CAS  Google Scholar 

  13. Gradman AH, Basile JN, Carter BL, Bakris GL. Combination therapy in hypertension. J Am Soc Hypertens. 2010;4(1):42–50.

    Article  PubMed  CAS  Google Scholar 

  14. Kotsis V, Stabouli S, Bouldin M, Low A, Toumanidis S, Zakopoulos N. Impact of obesity on 24-hour ambulatory blood pressure and hypertension. Hypertension. 2005;45(4):602–7.

    Article  PubMed  CAS  Google Scholar 

  15. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326(7404):1427.

    Article  PubMed  CAS  Google Scholar 

  16. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981–97.

    Google Scholar 

  17. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351(9118):1755–62.

    Article  PubMed  CAS  Google Scholar 

  18. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995–1003.

    Article  PubMed  CAS  Google Scholar 

  19. Mourad JJ, Waeber B, Zannad F, Laville M, Duru G, Andrejak M. Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach. J Hypertens. 2004;22(12):2379–86.

    Article  PubMed  CAS  Google Scholar 

  20. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122(3):290–300.

    Article  PubMed  Google Scholar 

  21. Hopkins KA, Bakris GL. Fixed-dose combination and chronic kidney disease progression: which is the best? Curr Opin Nephrol Hypertens. 2010;19(5):450–5.

    Article  PubMed  CAS  Google Scholar 

  22. Fung V, Huang J, Brand R, Newhouse JP, Hsu J. Hypertension treatment in a medicare population: adherence and systolic blood pressure control. Clin Ther. 2007;29(5):972–84.

    Article  PubMed  Google Scholar 

  23. Gradman AH, Basile JN, Carter BL, et al. Combination therapy in hypertension. J Am Soc Hypertens. 2010;4(2):90–8.

    Article  PubMed  CAS  Google Scholar 

  24. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713–9.

    Article  PubMed  Google Scholar 

  25. Yoshimura M, Kawai M. Synergistic inhibitory effect of angiotensin II receptor blocker and thiazide diuretic on the tissue renin-angiotensin-aldosterone system. J Renin Angiotensin Aldosterone Syst. 2010;11(2):124–6.

    Article  PubMed  CAS  Google Scholar 

  26. Chrysant SG. Using fixed-dose combination therapies to achieve blood pressure goals. Clin Drug Investig. 2008;28(11):713–34.

    Article  PubMed  CAS  Google Scholar 

  27. Chrysant SG, Stimpel M. Antihypertensive effectiveness of a very low fixed-dose combination of moexipril and hydrochlorothiazide. J Cardiovasc Pharmacol. 1998;31(3):384–90.

    Article  PubMed  CAS  Google Scholar 

  28. Lacourciere Y, Neutel JM, Schumacher H. Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials. Clin Ther. 2005;27(11):1795–805.

    Article  PubMed  CAS  Google Scholar 

  29. Dahlof B, Devereux RB, Julius S, et al. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. Hypertension. 1998;32(6):989–97.

    Article  PubMed  CAS  Google Scholar 

  30. Chrysant SG, Fagan T, Glazer R, Kriegman A. Effects of benazepril and hydrochlorothiazide, given alone and in low- and high-dose combinations, on blood pressure in patients with hypertension. Arch Fam Med. 1996;5(1):17–24.

    Article  PubMed  CAS  Google Scholar 

  31. Hypertension arm of ADVANCE defines extent of renal protection using perindopril/indapamide in type 2 diabetics. Cardiovasc J Afr. 2008;19(4):226.

    Google Scholar 

  32. Croxtall JD, Keating GM. Irbesartan/hydrochlorothiazide: in moderate to severe hypertension. Drugs. 2008;68(10):1465–72.

    Article  PubMed  CAS  Google Scholar 

  33. Sica DA. Chlorthalidone—a renaissance in use? Expert Opin Pharmacother. 2009;10(13):2037–9.

    Article  PubMed  CAS  Google Scholar 

  34. Bakris GL, Sica D, Weber M, et al. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens (Greenwich). 2011;13(2): 81–8.

    Article  CAS  Google Scholar 

  35. Frishman WH, Ram CV, McMahon FG, et al. Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: a randomized, double-blind, placebo-controlled, parallel-group study. The Benazepril/Amlodipine Study Group. J Clin Pharmacol. 1995;35(11):1060–6.

    PubMed  CAS  Google Scholar 

  36. Smith TR, Philipp T, Vaisse B, et al. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens (Greenwich). 2007;9(5):355–64.

    Article  CAS  Google Scholar 

  37. Chrysant SG. Amlodipine/ARB fixed-dose combinations for the treatment of hypertension: focus on amlodipine/olmesartan combination. Drugs Today (Barc). 2008;44(6):443–53.

    Article  CAS  Google Scholar 

  38. Cooper-Dehoff RM, Handberg EM, Mancia G, et al. INVEST revisited: review of findings from the International Verapamil SR-Trandolapril Study. Expert Rev Cardiovasc Ther. 2009;7(11):1329–40.

    Article  PubMed  CAS  Google Scholar 

  39. Cooper-Dehoff RM, Aranda Jr JM, Gaxiola E, et al. Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients—findings from the International Verapamil SR/Trandolapril Study (INVEST). Am Heart J. 2006;151(5):1072–9.

    Article  PubMed  Google Scholar 

  40. Scheen AJ, Krzesinski JM. Fixed combination perindopril-amlodipine (Coveram) in the treatment of hypertension and coronary heart disease. Rev Med Liege. 2009;64(4):223–7.

    PubMed  CAS  Google Scholar 

  41. Widimsky Jr J. Prevention of cardiovascular events by the antihypertensive treatment using amlodipine and perindopril in comparison with the use of atenolol and bendroflumethiazide. The ASCOT (Anglo-Scandinavian Outcomes Trail: blood pressure lowering arm) study results—multicentre, randomised, controlled trial. Landmark in the development of opinions on combination therapy in hypertension? Vnitr Lek. 2005;51(12):1394–9 [comment].

    PubMed  Google Scholar 

  42. Jamerson KA. The first hypertension trial comparing the effects of two fixed-dose combination therapy regimens on cardiovascular events: Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH). J Clin Hypertens (Greenwich). 2003;5(4 Suppl 3):29–35.

    Article  Google Scholar 

  43. Kjeldsen SE, Weber M, Oparil S, Jamerson KA. Combining RAAS and calcium channel blockade: ACCOMPLISH in perspective. Blood Press. 2008;17(5–6):260–9.

    Article  PubMed  CAS  Google Scholar 

  44. Braun N, Ulmer HJ, Ansari A, Handrock R, Klebs S. Efficacy and safety of the single pill combination of amlodipine 10 mg plus valsartan 160 mg in hypertensive patients not controlled by amlodipine 10 mg plus olmesartan 20 mg in free combination. Curr Med Res Opin. 2009;25(2):421–30.

    Article  PubMed  CAS  Google Scholar 

  45. Bramlage P, Wolf WP, Fronk EM, et al. Improving quality of life in hypertension management using a fixed-dose combination of olmesartan and amlodipine in primary care. Expert Opin Pharmacother. 2010;11(17):2779–90.

    Article  PubMed  CAS  Google Scholar 

  46. Punzi H, Neutel JM, Kereiakes DJ, et al. Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: the AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) study. Ther Adv Cardiovasc Dis. 2010;4(4):209–21.

    Article  PubMed  CAS  Google Scholar 

  47. Brown MJ, McInnes GT, Papst CC, Zhang J, MacDonald TM. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet. 2011;377(9762):312–20.

    Article  PubMed  CAS  Google Scholar 

  48. Yarows SA. Aliskiren/valsartan combination for the treatment of cardiovascular and renal diseases. Expert Rev Cardiovasc Ther. 2010;8(1):19–33.

    Article  PubMed  CAS  Google Scholar 

  49. Julius S, Weber MA, Kjeldsen SE, et al. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension. 2006;48(3):385–91.

    Article  PubMed  CAS  Google Scholar 

  50. Siscovick DS, Raghunathan TE, Psaty BM, et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med. 1994;330(26):1852–7.

    Article  PubMed  CAS  Google Scholar 

  51. Weinmann S, Glass AG, Weiss NS, Psaty BM, Siscovick DS, White E. Use of diuretics and other antihypertensive medications in relation to the risk of renal cell cancer. Am J Epidemiol. 1994;140(9):792–804.

    PubMed  CAS  Google Scholar 

  52. Psaty BM, Smith NL, Heckbert SR, et al. Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA. 2002;287(13):1680–9.

    Article  PubMed  CAS  Google Scholar 

  53. Ismail Z, Triggs EJ, Smithurst BA, Parke W. The pharmacokinetics of amiloride-hydrochlorothiazide combination in the young and elderly. Eur J Clin Pharmacol. 1989;37(2):167–71.

    Article  PubMed  CAS  Google Scholar 

  54. Kithas PA, Supiano MA. Spironolactone and hydrochlorothiazide decrease vascular stiffness and blood pressure in geriatric hypertension. J Am Geriatr Soc. 2010;58(7):1327–32.

    Article  PubMed  Google Scholar 

  55. Wu SL, Du X, Xing AJ, et al. Impact of patient compliance on the outcomes in hypertensive patients receiving hydrochlorothiazide based combination therapy with spironolactone or captopril. Zhonghua Xin Xue Guan Bing Za Zhi. 2008;36(12):1078–82.

    PubMed  Google Scholar 

  56. Hylander B, Danielson M, Eliasson K. Comparison of hydrochlorothiazide and slow release furosemide as adjuvant therapy to beta-blockers in the treatment of moderate hypertension. Acta Med Scand. 1987;222(2):137–42.

    Article  PubMed  CAS  Google Scholar 

  57. Haria M, Plosker GL, Markham A. Felodipine/metoprolol: a review of the fixed dose controlled release formulation in the management of essential hypertension. Drugs. 2000;59(1):141–57.

    Article  PubMed  CAS  Google Scholar 

  58. Galizzi JP, Fosset M, Lazdunski M. Properties of receptors for the Ca2+-channel blocker verapamil in transverse-tubule membranes of skeletal muscle. Stereospecificity, effect of Ca2+ and other inorganic cations, evidence for two categories of sites and effect of nucleoside triphosphates. Eur J Biochem. 1984;144(2):211–5.

    Article  PubMed  CAS  Google Scholar 

  59. Galizzi JP, Fosset M, Lazdunski M. [3H] verapamil binding sites in skeletal muscle transverse tubule membranes. Biochem Biophys Res Commun. 1984;118(1):239–45.

    Article  PubMed  CAS  Google Scholar 

  60. Kaesemeyer WH, Carr AA, Bottini PB, Prisant LM. Verapamil and nifedipine in combination for the treatment of hypertension. J Clin Pharmacol. 1994;34(1):48–51.

    PubMed  CAS  Google Scholar 

  61. Liebson PR, Amsterdam EA. Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET): implications for reduced cardiovascular risk. Prev Cardiol. 2009;12(1):43–50.

    Article  PubMed  Google Scholar 

  62. Bakris GL, Iyengar M, Lukas MA, Ordronneau P, Weber MA. Effect of combining extended-release carvedilol and lisinopril in hypertension: results of the COSMOS study. J Clin Hypertens (Greenwich). 2010;12(9):678–86.

    Article  CAS  Google Scholar 

  63. Gradman AH. Rationale for triple-combination therapy for management of high blood pressure. J Clin Hypertens (Greenwich). 2010;12(11):869–78.

    Article  Google Scholar 

  64. Deeks ED. Amlodipine/valsartan/hydrochlorothiazide: fixed-dose combination in hypertension. Am J Cardiovasc Drugs. 2009;9(6):411–8.

    Article  PubMed  CAS  Google Scholar 

  65. Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther. 2010;32(7):1252–69.

    Article  PubMed  CAS  Google Scholar 

  66. Elley CR, Toop L. A polypill is the solution to the pharmacological management of cardiovascular risk. J Prim Health Care. 2009;1(3):232–6.

    PubMed  Google Scholar 

  67. Wald DS, Wald NJ. The Polypill in the prevention of cardiovascular disease. Prev Med. 2011;52(1):16–7.

    Article  PubMed  Google Scholar 

  68. Majed M, Moradmand BS. A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy (‘polypill’) on cardiovascular risk factors. Arch Iran Med. 2011;14(1):78–80.

    PubMed  Google Scholar 

  69. Wagstaff AJ. Valsartan/hydrochlorothiazide: a review of its use in the management of hypertension. Drugs. 2006;66(14):1881–901.

    Article  PubMed  CAS  Google Scholar 

  70. Weir MR, Levy D, Crikelair N, Rocha R, Meng X, Glazer R. Time to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy. Am J Hypertens. 2007;20(7):807–15.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Hypertension, Department of Medicine, Philippine General Hospital, University of the Philippines College of Medicine, Taft Avenue, Manila, 1900, Philippines

    Raymond V. Oliva

  2. ASH Comprehensive Hypertension Center, Department of Medicine, University of Chicago Medicine, 5841 S. Maryland Avenue, MC1027, Chicago, IL, 60637, USA

    George L. Bakris

Authors
  1. Raymond V. Oliva
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George L. Bakris
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Raymond V. Oliva .

Editor information

Editors and Affiliations

  1. ASH Comprehensive Hypertension Center, Department of Medicine, University of Chicago Medical Center, 5841 S. Maryland Avenue, MC1027, Chicago, 60637, Illinois, USA

    George L. Bakris

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media New York

About this chapter

Cite this chapter

Oliva, R.V., Bakris, G.L. (2012). Combination Therapy in Hypertension Treatment. In: Bakris, G. (eds) Managing the Kidney when the Heart is Failing. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-3691-1_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-3691-1_5

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4614-3690-4

  • Online ISBN: 978-1-4614-3691-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation